The Expression And Significance Of Angiogenin-2 And Vegf In Acute Leukemia

Objective: To research the relation between serum levels of angiogenin-2(Ang-2), vascular endothelial growth factor (VEGF) and acute leukemia (AL) in different periods. In primary untreated AL patients, investigate the relationship between serum levels of Ang-2, VEGF and WBC in peripheral blood, blast cell of bone marrow, lactate dehydrogenase (LDH),β2-microglobulin (BMG) andα-L fucosidase (AFU). At the same time, investigate the correlation between Ang-2, VEGF. Further to explore the correlation of Ang-2 and VEGF with the occurrence and development of AL. Through the study, provide the theoretical basis of antiangiogenesis therapy in AL.Methods: Serum levels of Ang-2 and VEGF in 24 primary untreated patients,18 complete remission(CR),13 Non-remission(NR),7relapsed patients with AL were measured by enzyme-linked immunosorbent assay (ELISA) to compare with those of 20 healthy persons in control group.Results: 1. The examination during different periods indicated serum levels of Ang-2 in primary untreated patients, CR, NR,relapsed patients,normal control group were 21.70±4.96ng/ml, 7.93±2.86ng/ml, 21.04±4.48ng/ml, 22.74±4.07ng/ml,6.13±2.16ng/ml respectively. Via't'examination, it was discovered that serum levels of Ang-2 in primary untreated patients were apparently higher than those of normal control group, which was statistically significant (P<0.01). Serum levels of Ang-2 in CR decrease obviously, indicating no clear difference from those in normal control groups, which was considered as non statistical significance (P>0.05). Serum levels of Ang-2 in relapsed and NR patients were greatly higher than those of normal control and CR group, which was statistically significant (P<0.01).2. The examination during different periods indicates serum levels of VEGF in primary untreated patients, CR, NR,relapsed patients,normal control group were 235.83±50.67pg/ml,99.17±15.76pg/ml,265.23±31.05pg/ml,284.87±83.07pg/ml,94.85±15.13pg/ml respectively. Via't'examination, serum levels of VEGF in primary untreated patients were obviously higher than those of normal control group, which was statistically significant (P<0.01). Serum levels of VEGF in CR decreased sharply, showing no significant difference from those in normal control groups, which was considered as non statistical significance (P>0.05).Serum levels of VEGF in relapsed and NR patients was greatly higher than those of normal control and CR group, this difference was statistically significant (P<0.01).3. The analysis of serum levels of Ang-2 and clinically relevant factors in primary untreated patients indicated that there was no correlation between Serum levels of Ang-2 and WBC in peripheral blood, blast cell of bone marrow and AFU(r =0.25,0.03,0.82,P >0.05), but correlated with LDH , BMG (r = 0.45, 0.58, P< 0. 05, < 0. 01).4. The analysis of serum levels of VEGF and clinically relevant factors in primary untreated patients indicated, there was no correlation between Serum levels of VEGF and WBC in peripheral blood , blast cell of bone marrow and AFU (r =0.30, 0.25, 0.21, P>0.05), but correlated with LDH, BMG (r = 0.45, 0.58,P< 0. 05, < 0. 01).5. There was a positive correlation between serum levels of Ang-2 and VEGF in primary untreated patients(r = 0.50, P <0.05).Conclusions: Serum levels of Ang-2 and VEGF are associated with AL in different periods. In primary untreated patients, Ang-2 and VEGF possibly play a different role .There is a positive correlation between serum Ang-2 and VEGF in primary untreated patients. Serum levels of Ang-2 and VEGF have a close relationship with the occurrence and development of AL. VEGF may promote angiogenesis of AL by raise Ang-2. Both of them may be used as diagnose disease, understanding of one's illness, observe efficacy and prognostic indicators in AL. Therefore, specific Ang-2 and VEGF inhibition may represent an effective antiangiogenic strategy for treating patients with AL.